

TITLE OF THE INVENTION

PROCESSES FOR PREPARING BICYCLO [3.1.0] HEXANE DERIVATIVES, AND
INTERMEDIATES THERETO

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. § 119(e) to U.S. provisional application serial no. 60/518,391, filed November 7, 2003.

FIELD OF THE INVENTION

The present invention relates to processes for the preparation of bicyclo[3.1.0]hexane derivatives which are useful as metabotropic glutamate receptor modulators. The invention is also related to novel intermediate compounds which are prepared during such processes, and to the hydrochloride salt of (+)-(1*R*, 2*S*, 5*S*, 6*S*)-2-amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid, and polymorphs thereof.


BACKGROUND OF THE INVENTION

The excitatory amino acids, including glutamate, modulate a variety of physiological processes in the mammalian central nervous system (CNS), such as long-term potentiation (learning and memory), the development of synaptic plasticity, motor control, respiration, cardiovascular regulation, and sensory perception.

Glutamate acts via at least two distinct classes of receptors. One class is composed of the ionotropic glutamate (iGlu) receptors that act as ligand-gated ionic channels. The second class is the G-protein or second messenger-linked "metabotropic" glutamate (mGluR) receptor. Both classes of receptors appear to mediate normal synaptic transmission along excitatory pathways, and also to participate in the modification of synaptic connections during development and throughout life. Schoepp, Bockaert, and Sladeczek, *Trends in Pharmacol. Sci.*, 11, 508 (1990); McDonald and Johnson, *Brain Research Reviews*, 15, 41 (1990).

Various functionalized bicyclo[3.1.0]hexane derivative compounds have been recognized as mGluR modulators. The mGluR modulators are therapeutically useful for the treatment or prevention of psychiatric disorders, schizophrenia, anxiety and associated diseases, depression, bipolar disorder, and epilepsy; and neurological diseases, such as drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, dyskinesia associated with muscular stiffness, cerebral ischemia, cerebral failure, myelopathy, and head trauma. For example, U.S. Patent No. 6,333,428, issued


December 25, 2001, discloses certain mGluR agonists which are 2-amino-6-fluorobicyclo[3.1.0]hexane derivatives of the formula below:



wherein R¹ and R² are each selected from the group consisting of


- 5 (1) hydrogen;
 (2) C₁₋₁₀ alkyl;
 (3) C₃₋₈ cycloalkyl; and
 (4) C₃₋₈ cycloalkyl-C₁₋₅ alkyl;

and pharmaceutically acceptable salts thereof. The '428 patent states that the compounds of the
 10 invention may be in racemic form, or may be in enantiomeric form. The '428 patent also discloses
 certain novel intermediates of the formula below:




15 wherein R¹ is as defined above.

U.S. Patent No. 6,160,009, issued December 12, 2000, discloses a class of functionalized bicyclo[3.1.0]hexane derivatives, which are therapeutically useful as mGluR agonists, of the formula below:



20 wherein R¹ and R² could together represent =O.

U.S. Patent No. 5,750,566, issued May 12, 1998, discloses an mGluR agonist of the formula below:



which is known as LY 354740.


Preparation of the mGluR modulators and intermediates disclosed above has been disclosed in the aforementioned patents, in Nakazato et al., *J. Med. Chem.*, 2000, 43, 4893-4909, and in WO 02/00595 (which is published in English as EP 1 295 862). However, the disclosed syntheses involve drawbacks which make them unsuitable for large scale production. For example, the syntheses disclosed in the '428 patent and in Nakazato call for the preparation of racemic intermediates, which must then be subjected to complicated separation procedures involving HPLC, resulting in low productivity. Typically, the known synthetic methods also require the use of expensive and hazardous reagents, such as Pd(OAc)₂ and (PhSe)₂, which must be present in stoichiometric amounts, and CH₂N₂. The synthetic method of Nakazato also requires a harsh hydrolysis using H₂SO₄ at high temperatures (145°C) for five days as the last step of the synthesis, resulting in a low yield, and requires a difficult isolation of the final product from a hydantoin derivative precursor.

It will be appreciated that the mGluR modulators disclosed in U.S. Patent Nos. 6,333,428, 6,160,009 and 5,570,566, are useful as therapeutic agents. As such, there is a need for a development of a process for the preparation of these compounds, which is readily amenable to scale-up, uses cost-effective and relatively safe reagents, and is therefore capable of practical application to large scale manufacture.

Applicants have now discovered a novel synthesis of a class of enantiomerically pure functionalized bicyclo[3.1.0]hexane derivative mGluR modulators and of enantiomerically pure intermediate compounds.

SUMMARY OF THE INVENTION

The present invention concerns novel processes for the synthesis of a class of functionalized bicyclo[3.1.0]hexane derivative mGluR modulators of formula (I)



wherein R¹ and R² are independently selected from the group consisting of

- (1) hydrogen,
- (2) C₁₋₁₀ alkyl,
- (3) C₃₋₈ cycloalkyl, and
- (4) -(CH₂)_n-phenyl

5 wherein n is 1 or 2; and said alkyl, cycloalkyl and phenyl are unsubstituted or substituted with one or more halogen, hydroxy, C₁₋₆ alkyl or C₁₋₆ alkoxy;


X is selected from the group consisting of

- (1) halogen, and
- (2) hydrogen; and

10 Q is -CH₂- or -C(=O)-;

and pharmaceutically acceptable salts thereof.

The invention further relates to novel processes for the preparation of compounds of formula (II)



15 wherein R³ is selected from the group consisting of

- (1) -OH,
- (2) -O-R^a, and
- (3) -NR^bR^c,

wherein R^a is selected from the group consisting of


- 20 (a) C₁₋₁₀ alkyl, and
- (b) C₃₋₈ cycloalkyl,

and R^a is unsubstituted or substituted with one or more

- (i) C₁₋₁₀ alkoxy,
- (ii) hydroxy,
- 25 (iii) halogen,
- (iv) SR^d,
- (v) aryl, unsubstituted or substituted with one or more hydroxy, C₁₋₁₀ alkoxy, C₁₋₁₀ alkyl or halogen,
- (vi) heteroaryl, unsubstituted or substituted with one or more hydroxy, C₁₋₁₀ alkoxy, C₁₋₁₀ alkyl or halogen, and
- 30 (vii) NR^eR^f;

R^b, R^c, R^e and R^f are selected from the group consisting of

- (a) hydrogen,
 (b) C₁₋₁₀ alkyl, and
 (c) C₃₋₈ cycloalkyl,
 and when R^b, R^c, R^e or R^f are C₁₋₁₀ alkyl or C₃₋₈ cycloalkyl, said C₁₋₁₀ alkyl
 5 and C₃₋₈ cycloalkyl are unsubstituted or substituted with one or more
- (i) hydroxy,
 (ii) C₁₋₁₀ alkoxy,
 (iii) SR^d,
 (iv) aryl, unsubstituted or substituted with one or more hydroxy, C₁₋₁₀
 10 alkoxy, C₁₋₁₀ alkyl or halogen, and
 (v) heteroaryl, unsubstituted or substituted with one or more hydroxy, C₁₋₁₀
 alkoxy, C₁₋₁₀ alkyl or halogen, and
 (vi) NR^gR^h;
 wherein R^g and R^h are hydrogen, C₁₋₁₀ alkyl or C₃₋₈ cycloalkyl;
 15 or R^b and R^c, together with the N atom to which they are attached, form a group



wherein r is 1 or 2, and the NR^bR^c group may be unsubstituted or substituted at
 the ring carbon atoms by one or more

- (i) hydroxy,
 (ii) C₁₋₁₀ alkoxy,
 (iii) SR^d,
 (iv) aryl, unsubstituted or substituted with one or more hydroxy, C₁₋₁₀
 20 alkoxy, C₁₋₁₀ alkyl or halogen, and
 (v) heteroaryl, unsubstituted or substituted with one or more hydroxy, C₁₋₁₀
 25 alkoxy, C₁₋₁₀ alkyl or halogen, and
 (vi) NR^gR^h,

R^d is hydrogen or C₁₋₁₀ alkyl;

30 X is selected from the group consisting of

- (1) halogen, and
 (2) hydrogen; and

R⁴ is selected from the group consisting of

- (1) hydrogen,
 (2) C₁₋₁₀ alkyl,
 (3) Si-(R⁹)(R¹⁰)(R¹¹),
 (4) C(=O)-R¹²,
 (5) CH₂-phenyl, wherein said phenyl is unsubstituted or substituted with one or more substituents selected from the group consisting of nitro, halogen, C₁₋₁₀ alkyl and C₁₋₁₀ alkoxy,
 (6) (CH₂)_p-O-(CH₂)_q-X'-R¹⁴,
 (7) tetrahydropyranyl,

wherein R⁹, R¹⁰ and R¹¹ are each C₁₋₁₀ alkyl or phenyl, and R¹⁴ is selected from the group consisting of

- (a) hydrogen,
 (b) C₁₋₁₀ alkyl,


p is 1 or 2;

q is an integer of from 1-10; and


X' is O or a bond;

and salts thereof.

The invention is also related to novel processes for the preparation of compounds of formula (XII)



or its enantiomer (XII')



wherein R³ and X are as defined above, and salts thereof.

Compounds of formulas (II), (XII) and (XII') are intermediates prepared in the synthesis of the mGluR modulators of formula (I). Processes for using compound (XII) or (XII') to form mGluR modulators of formula (I) are disclosed in the aforementioned '566, '428 and '009 patents, and in Nakazato et al., *J. Med. Chem.*, 2000, 43, 4893-4909. The invention also relates to certain novel intermediates which are prepared during the synthesis of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS


The invention is described in connection with the appended drawings, in which:

FIG. 1 is the x-ray powder diffraction (XPRD) pattern of a crystal form of the hydrochloride salt of (+)-(1*R*, 2*S*, 5*S*, 6*S*)-2-amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid; and

FIG. 2 depicts the differential scanning calorimetry curve for a crystal form of the hydrochloride salt of (+)-(1*R*, 2*S*, 5*S*, 6*S*)-2-amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to processes for preparing functionalized bicyclo[3.1.0] hexane derivatives of formula (I)



wherein R^1 and R^2 are independently selected from the group consisting of

- (1) hydrogen,
- (2) C_{1-10} alkyl,
- (3) C_{3-8} cycloalkyl, and
- (4) $(CH_2)_n$ -phenyl,

wherein n is 1 or 2, and said alkyl, cycloalkyl and phenyl are unsubstituted or substituted with one or more halogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy;


X is selected from the group consisting of

- (1) halogen, and
- (2) hydrogen; and

Q is $-CH_2-$ or $-C(=O)-$;


and pharmaceutically acceptable salts thereof.

In one embodiment, the invention is directed to a process for preparing compounds of formula (IA):




wherein X, R¹ and R² are as defined above.

In this embodiment, the invention comprises oxidizing an intermediate compound of formula (II):




wherein X, R³ and R⁴ are as defined above;


to form a compound of formula (IV):



deprotecting the hydroxyl group of the compound of formula (IV) to form a compound of formula (V):



and reacting the compound of formula (V) with the compound of formula (VI)



wherein each R⁵ and R⁶ is independently selected from the group consisting of

- (1) hydrogen,
- (2) C₁-10 alkyl,

(3) C₃₋₈ cycloalkyl, and

(4) (CH₂)_m-phenyl,

wherein m is 0, 1 or 2, and


R⁷ is selected from the group consisting of

5


(1) hydrogen, and

(2) Si-(R⁹)(R¹⁰)(R¹¹), wherein R⁹, R¹⁰ and R¹¹ are each C₁₋₁₀ alkyl or phenyl;

to give a compound of formula (VII):




The compound of formula (VII) is then oxidized to give a compound of formula (VIII):




10

which is converted to a compound of formula (IX):



The compound of formula (IX) is then converted to the desired compound of formula (IA):



15 wherein X, R¹ and R² are as defined above.

In preferred embodiments of the process of preparing compounds of formula (IA), X is fluoro. In other preferred embodiments, X is hydrogen.

In preferred embodiments of the process of making compounds of formula (IA), R¹ and R² are hydrogen.




5 In preferred embodiments of the process of preparing compounds of formula (IA), R³ is methoxy, ethoxy or benzyloxy.

In the process of preparing compounds of formula (IA), preferred R⁴ groups are TBS, TMS and TES. A preferred R⁷ group is TMS.

10 In preferred embodiments of the process of preparing compounds of formula (IA), R⁵ and R⁶ are selected from the group consisting of methyl and phenyl. It is preferred that R⁵=R⁶.


In preferred embodiments of the process of preparing compounds of formula (IA), the step of converting compound (IX) to compound (I) comprises hydrolysis of compound (IX).

The invention is also directed to novel intermediate compounds of formulas (VII), (VIII) and (IX):




which are prepared during the synthesis of the mGluR modulators of formula (I); and salts thereof. In compounds (VII), (VIII) and (IX), R^3 , R^5 , R^6 and X are as defined above.

The present invention is also directed to processes for preparing the intermediate compounds of formula (II):




5

wherein R^3 , X and R^4 are as defined above, and salts thereof. In this process, a compound of formula (X):



10

wherein X is hydrogen and R^3 is as defined above, is subjected to epoxidation, for example by reaction with a peroxide such as *tert*-butyl hydroperoxide, or other oxidants (including peracids such as perbenzoic acid and peracetic acid) preferably in the presence of a metal catalyst, such as $VO(acac)_2$. The hydroxy group of compound (X) may then be protected, for example with TBS or TMS, to result in a compound of formula (XI):




15

wherein X is hydrogen and R^4 is as defined above. The compound may then be fluorinated (wherein X is fluorine). Alternatively, compound (X) may first be fluorinated (wherein X is F). The fluorinated compound may then be subjected to epoxidation as described above.


20

Alternatively, formation of the epoxide derivative may occur via halohydrin, by reaction with a halogen source. For example, a compound of formula (X) may be reacted with N-bromo succinimide, followed by treatment with a base, and the epoxide product is then isolated.

The protected epoxide derivative (XI) is then reacted with a suitable base in the presence of a Lewis Acid to afford a compound of formula (II):



wherein X, R³ and R⁴ are as defined above. Compound (II) may then be oxidized to give compound (IV):



which may then be converted according to the process steps described above, to form compounds of formula (IA).

Alternatively, compounds of formula (IV) may be converted to compounds of formula (IA) according to methods described in the prior art. For example, Nakazato, *J. Med. Chem.* 2000, 43, 4893-4909 describes the use of a compound of formula (IV) to form a compound of formula (IA) in Scheme 5 at page 4898. The process taught by Nakazato requires formation of a dithioketal, followed by hydantoin derivative.

U.S. Pat. No. 6,160,009 describes the use of a compound of formula (IV) to form a compound of formula (IA) at columns 8-13. The reaction proceeds via a hydantoin derivative.




In preferred embodiments of the process of preparing compounds of formula (II), R³ is methoxy, ethoxy or benzyloxy.

In preferred embodiments of the process of preparing compounds of formula (II), X is fluoro. In other preferred embodiments, X is hydrogen.


In the process of preparing compounds of formula (II), preferred R⁴ groups are TBS, TMS and TES.

In other preferred embodiments of the process, the oxidation of compound (II) comprises contacting compound (II) with RuCl₃ and an oxidizing agent. Preferred oxidizing agents are bleaches. A preferred bleach is NaClO.

The invention is also directed to novel intermediate compounds of formulas (XA), (XD), (IVA) and (II), as depicted below:




5




In compounds (XA), (XI), (IVA) and (II), R³, X and R⁴ are as defined above.

The invention is also directed to processes for preparing intermediate enone compounds of formula (XII):




10

and its enantiomer (XII'):




wherein R^3 and X are as defined above; and salts thereof.

In an embodiment of this process for preparing a compound of formula (XII), a compound of formula (II)




wherein X, R^3 and R^4 are as defined above, is subjected to a reaction to form a compound of formula (XIII), having a leaving group R^8 as follows:




wherein R^8 is selected from the group consisting of

- (1) halogen, and
- (2) $O-SO_2-R^{12}$ wherein R^{12} is selected from the group consisting of
 - (a) C_{1-10} alkyl,
 - (b) C_{1-10} perfluoroalkyl,
 - (c) phenyl which is substituted or unsubstituted with one or more substituents selected from the group consisting of nitro, halogen, C_{1-10} alkyl, or C_{1-10} alkoxy.


Thereafter, the R^4 group is removed to afford the hydroxy ester derivative (XIV) below:




which is then oxidized to afford the desired [3.1.0]-bicyclic- α , β unsaturated ketone of formula (XII):



In an embodiment of this process for forming a compound of formula (XII'), a compound of formula (II) is oxidized to form a compound of formula (IV)



wherein X, R³ and R⁴ are as defined above. Compound (IV) is then subjected to an elimination reaction, for example by reaction with a base such as DBU, to give a compound of formula (XII')



which is the enantiomer of the corresponding compound of formula (XII).

The enone compound of formula (XII) or (XII') may be converted to a compound of formula (I) according to methods known in the prior art. For example, Nakazato, *J. Med. Chem.* 2000, 43, 4893-4909 describes the use of a compound of formula (XII) to form a compound of formula (IA) in Scheme 5 at page 4898.

U.S. Pat. No. 5,750,566 describes the use of a compound of formula (XII) to form compounds of formula (I) wherein Q is CH₂, at column 12 in Scheme IV.

Dominguez et al, *Tetrahedron: Asymmetry*, 1997, 8, 511-514 describes the use of a compound of formula (XII) to form compounds of formula (I) wherein Q is CH₂, at Scheme 2 at page 513. The process requires formation of a hydantoin derivative.


In preferred embodiments of the synthesis of compounds of formula (XII) and (XII'), R³ is methoxy, ethoxy or benzyloxy.

In preferred embodiments of synthesis of compounds of formula (XII) and (XII'), X is fluoro. In other preferred embodiments, X is hydrogen.

In the synthesis of compounds of formula (XII) and (XII'), preferred R⁴ protecting groups are TBS, TMS and TES.

In the synthesis of compounds of formula (XII) and (XII'), preferred R⁸ groups include O-tosyl (*para* toluenesulfonyl), O-mesyl and O-triflate.

The invention is also directed to the hydrochloride salt of compounds of formula (I). In preferred embodiments, the hydrochloride salt is the salt of the compound of formula (I) wherein X is fluoro and R¹ and R² are both hydrogen, denoted compound (I')



which is (+)-(1*R*, 2*S*, 5*S*, 6*S*)-2-amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid. The invention is also directed to a novel crystal polymorph of the hydrochloride salt of compound (I').

10 Definitions

As used herein, the term "Strecker synthesis reaction" or "Strecker reaction" refers to a reaction known to those skilled in the art of organic synthesis, to prepare alpha amino nitriles

As used herein, the term "substantially enantiomerically pure form" means that the desired enantiomer is present in at least 50% e/e (enantiomeric excess) relative to the undesired enantiomer.

15 As used herein, the term "Lewis Acid" refers to a compound which is capable of accepting electrons.

As used herein, the term "aryl" refers to a polyunsaturated aromatic hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) which can be fused together or linked covalently. Non-limiting examples of aryl groups include phenyl, naphthyl and biphenyl.

20 As used herein, the term "heteroaryl" refers to a polyunsaturated aromatic ring having at least one heteroatom (nitrogen, oxygen or sulfur) in the ring chain. A heteroaryl group can be a single ring or multiple rings (preferably from 1 to 3 rings) which can be fused together or linked covalently. Non-limiting examples of heteroaryl groups include pyrrole, pyrazole, imidazole, pyridine, pyrazine, pyrimidine, furan, pyran, oxazole, isoxazole, purine, benzimidazole, quinoline, isoquinoline, indole and
25 the like.

When a heteroaryl group as defined herein is substituted, the substituent may be bonded to a ring carbon atom of the heteroaryl group, or to a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution. Preferably, the substituent is bonded to a ring carbon atom.

30 As used herein, the term "halogen" refers to fluorine, chlorine and bromine. A preferred halogen is fluorine.

As used herein, the term "alkyl," by itself or as part of another substituent, means a straight or branched chain hydrocarbon radical having the number of carbon atoms designated (*e.g.*, C₁₋₁₀ alkyl means an alkyl group having one to ten carbon atoms). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, pentyl, hexyl and the like.

As used herein, the term "alkoxy," by itself or as part of another substituent, means the group O-alkyl, wherein alkyl is as defined above, to include straight or branched alkyl groups.


As used herein, the term "cycloalkyl," by itself or as part of another substituent, means a saturated cyclic hydrocarbon radical having the number of carbon atoms designated (*e.g.*, C₃₋₈ cycloalkyl means a cycloalkyl group having three to eight carbon atoms).

As used herein, the term "pharmaceutically acceptable" refers to molecular entities and compositions that are "generally regarded as safe," *e.g.*, that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S.

Pharmacopeia or other generally recognized pharmacopeia for use in animals, and, more particularly, in humans.

In one embodiment, the process of the invention is depicted in Scheme 1 below.


Scheme 1



wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and X are as defined above.


The optically active trans hydroxy ester **1** may be obtained according to the teachings of Partridge et al., *Org. Synth* **1985**, 83, 44. See also Tolstikov et. al, *J. Org. Chem. USSR* **1989**, 25(1.2) and **1990**, 26 (7.1, 1274). The trans hydroxy ester **1** is preferably more than 90% e/e, more preferably more than 95% e/e, even more preferably more than 96% e/e.

5 The trans hydroxy ester **1** may be fluorinated without protecting the secondary alcohol, to give compound **2**.




One method of achieving the desired fluorination is by reaction with the fluorinating agent, such as N-fluorobenzenesulfonimide (NFSI) with a strong base in a suitable solvent, for example tetrahydrofuran. It is preferred that the reaction occur at temperatures of less than -65°C, preferably less than -75°C, most preferably less than -78°C. Suitable strong bases include lithium diisopropylamide (LDA), lithium tetramethylpiperizide, lithium hexamethyldisilazide (LHMDS), or corresponding potassium or sodium salts.

15 Stereoselective epoxidation of **2** may then be achieved by reaction in toluene with an oxidizing agent, such as a peroxide derivative (for example *tert*-butyl hydroperoxide), and a catalyst (for example, a catalytic amount of vanadyl acetylacetonate (VO(acac)₂). It is preferred that the reaction occur at from about 0°C to about 40°C.




Alternative oxidizing agents include *meta* chloroperoxybenzoic acid (mCPBA). The resulting epoxide **3** is obtained as a trans isomer.

20 Alternatively, the trans hydroxy ester **1** may be first subjected to stereoselective epoxidation, and the resulting epoxide **2'** may be fluorinated to yield compound **3**.




Epoxidation may also be obtained by treatment of 1 (or fluorinated compound 2) with a halogenating agent, for example NBS or NIS, in a suitable solvent (for example, a mixture of DMSO and water). Compound 1 then forms a halohydrin derivative, which is cyclized with a base (such as DBU) to form the epoxide.

Protection of the hydroxyl group of 3 with a protecting agent R^4 , for example a silyl protecting agent such as *tert* butyldimethylsilyl chloride (TBSCl) under suitable conditions, for example in imidazole and DMF, produces the protected epoxide compound 4, as shown below:




The protected epoxide 4 may then be subjected to an intramolecular epoxide opening cyclopropanation reaction. The reaction proceeds with addition of a base in the presence of a Lewis Acid, such as Et_3Al . Preferably, the reaction occurs at about $-50^\circ C$.


In a preferred embodiment, compound 4 is first treated with Et_3Al and LiHMDS is then added dropwise. The reaction may proceed for 0.5 to 6 hours, at a temperature of from $-20^\circ C$ to $-80^\circ C$. A preferred time is about 1 hour. A preferred temperature is about $-60^\circ C$. Alternative Lewis Acids which may be used in the reaction include, $RTi(OR)_3$, $R_2Ti(OR)_2$, $RAiX_2$ or R_2AlX , wherein X is a halogen or an inorganic radical and each R is a hydrocarbon group. Exemplarily Lewis Acids include $Al(OiPr)_3$, $Ti(OiPr)_4$, BF_3 etherate, Et_2Zn , Et_3Al and $Sc(OTf)_3$. Compound 5 is obtained in the desired stereoisomeric form.



Oxidation of the resulting free alcohol and removal of the protecting group provides bicyclic hydroxy ketone **7** (compound II). Preferred oxidizing agents include reagent grade sodium hypochlorite solution or commercial bleach. The reaction may proceed in the presence of a catalytic amount of RuCl_3 and in the presence of acetic acid (1.5 equivalents) at 0°C in acetonitrile. The excess sodium hypochlorite should then be removed (for example, by quenching with isopropyl alcohol). The addition of an acid (e.g., 20 mol% of 1M HCl) to the acetonitrile solution cleaves the protecting group R^4 .




Compound **7** may be protected as a ketal **8**, by reaction with diol derivatives. A preferred R^7 group is TMS.




The reaction proceeds in the presence of acid (e.g., 0.1 equivalent), at from about 0°C to about -10°C . A preferred acid is TfOH or TfOTMS.

Oxidation of the secondary alcohol of **8** yields ketone **9**.



The oxidation reaction may proceed with any oxidizing conditions such as Swern conditions. Alternatively, the oxidation may proceed in the presence of RuCl_3 (0.5 mol%), with NaClO in acetonitrile and acetic acid, at from 0°C to room temperature.

Compound **9** is then subjected to a Strecker reaction with ammonia. The reaction may proceed in an alcohol solvent (e.g., methanol) with ammonia at room temperature.



Subsequently, TMSCN may be added at from -10°C to 0°C . TMSCN can be replaced with KCN/NaCN in the presence of acids. A titanium compound, such as titanium isopropoxide ($\text{Ti}(\text{OiPr})_4$), may be used to promote the reaction. The reaction yields the desired amino-nitrile **10** with high diastereoselectivity.

Compound **10** is then subjected to hydrolysis to provide the desired 2-amino-6-fluorobicyclo[3.1.0]hexane (compound **11**).




- 10 The hydrolysis reaction may proceed in 5 hours using a 1:3 mixture of acetic acid and 8 M HCl at 75°C . Alternatively, the reaction may proceed in the presence of 60% H_2SO_4 , at about 100°C , for about 2 hours, or alternatively by treatment with acetic acid/ H_2SO_4 at 60°C , for about 2 hours.

Thereafter, the desired compound **11** may be isolated as the hydrochloride salt, according to methods known to those skilled in the art.

- 15 In another embodiment, the process of the invention is depicted in Scheme 2 below.

Scheme 2



wherein X, R^3 , R^4 and R^8 are as defined above.


In Scheme 2, optically active trans-hydroxy ester 12 was obtained as taught above in the description of scheme 1. Epoxidation of 12 proceeded in a diastereoselective manner to afford epoxide 13, protection of the hydroxyl group in 13 gave 14, and treatment of 14 with a Lewis acid followed by a base produced a bicyclo[3.1.0] compound 15. The use of the enantiomer of 12, which is disclosed in Partridge et al., *Org. Synth* 1985, 83, 44, will afford the synthesis of the enantiomers of 13, 14, and 15.

The mono-protected [3.1.0] bicyclic diol 15 (which is identical to 5 from scheme 1) is transformed to a [3.1.0] bicyclic α,β -unsaturated ketone. In this scheme, the hydroxyl group in the alcohol 15 is converted to a leaving group R^8 , and the protecting group R^4 is removed to afford hydroxy ester 17. Suitable R^8 leaving groups include sulfonate (for example, *para*-toluenesulfonate) and halides. Oxidation of 17 is induced by the elimination of the R^8 leaving group to afford a [3.1.0] bicyclic α,β -

unsaturated ketone 18, which can be used for the synthesis of mGluR agonists 19 (which is identical to 11 from scheme 1) and 20, according to the teachings of U.S. Pats. Nos. 5,750,566, 6,333,428 and 6,160,009, and Nakazoto et al., *J. Med. Chem.*, 2000, 43, 4893-4909.

In another embodiment, the process of the invention is depicted in scheme 3 below:

Scheme 3



wherein X, R³ and R⁴ are as defined above. Scheme 3 depicts a synthesis of the enantiomer of enone 18 (from scheme 2).


The chemical structures described above include each of the enantiomers either in enantiomerically pure form or in mixture form.

The starting materials and reagents for the processes described herein are either commercially available or are known in the literature or may be prepared following literature methods described for analogous compounds. The skills required in carrying out the reaction and purification of the resulting reaction products are known to those in the art. Purification procedures include crystallization, distillation, normal phase or reverse phase chromatography.

The following examples are provided for the purpose of further illustration only and are not intended to be limitations on the disclosed invention. Examples 1-10 illustrate the method of scheme 1. Examples 11-15 illustrate the method of scheme 2. Examples 16 and 17 illustrate the method of scheme 3.

EXAMPLE 1


Methyl fluorof(1*R*,5*R*)-5-hydroxycyclopent-2-en-1-yl]acetate 2



To a solution of diisopropylamine (10.8 mL, 76.8 mmol) in THF (28 mL), was added a solution of butyllithium (28.2 mL, 70.4 mmol, 2.5 M in hexanes) over 40 min while the inside temperature was maintained between 0 °C and 5 °C. The resulting solution was stirred at 0 °C for 3 min before cooled to -78 °C by dry ice-acetone bath. A solution of ester 1 (5.00 g, 32.0 mmol) in THF (41.3 mL) was added dropwise to the LDA solution over 45 min while the inside temperature was maintained below -73 °C, and the resulting solution was stirred at -78 °C for 20 min to form an orange (or dark orange) solution of dianion. A separate flask was charged with *N*-fluorobenzenesulfonimide (14.1 g, 44.8 mmol) and THF (62 mL), and the resulting solution was cooled to -96 °C by liquid nitrogen-acetone bath. The solution of the dianion was added via an addition funnel to the suspension of the fluorinating reagent over 1 h while the internal temperature was maintained around -95 °C. The funnel and the flask were flushed with 2.5 mL of THF into the reaction mixture. The resulting mixture was stirred at -96 °C for 1 h before warmed to -80 °C over 30 min. Acetic acid (11 mL) in THF (5 mL) was added slowly over 7 min. The mixture was allowed to warm to ambient temperature after the addition of MTBE (100 mL). The resulting solid was removed by filtration and washed thoroughly with MTBE (70 mL x 6). The combined filtrate and wash were filtered again and analyzed by HPLC. The chemical yield was determined to be 86%. The filtrate was passed through a short plug of silica gel (30 g), and the plug was washed with MTBE (200 mL). The combined MTBE solutions were concentrated under reduced pressure. The residue was dissolved in EtOAc (250 mL) and washed with saturated aqueous NaHCO₃ (170 mL). The aqueous layer was back-extracted with EtOAc (60 mL x 2). The combined organic solutions were washed with brine (60 mL) and dried over Na₂SO₄. Evaporation of solvent gave the crude ester, which was subjected to bulb-to-bulb distillation (1.6 Torr) to afford the ester as yellow oil. Analytically pure sample was obtained by further flash silica gel column chromatography as colorless oil. ¹H NMR (400 MHz, CDCl₃): δ 5.84 (m, 1 H), 5.55 (m, 1 H), 4.95 (dd, *J* = 48.8, 5.5 Hz, 1 H), 4.49 (dt, *J* = 7.2, 4.6 Hz, 1 H), 3.82 (s, 3 H), 3.11 (dm, *J* = 24.4 Hz, 1 H), 2.75 (m, 1 H), 2.51 (s, 1 H), 2.33 (m, 1 H); ¹³C NMR (101 MHz, CDCl₃): δ 170.02 (d, *J* = 24.1 Hz), 132.27, 126.13 (d, *J* = 5.0 Hz), 89.52 (d, *J* = 188.0 Hz), 73.92 (d, *J* = 4.0 Hz), 57.12 (d, *J* = 20.1 Hz), 52.64, 41.85; ¹⁹F NMR (376 MHz, CDCl₃): -196.5; IR (film) 3409, 3059, 1744, 1439, 1288, 1209, 1153, 1099, 1048, 951, 733 cm⁻¹; [α]_D²⁵ = -123.5 (c 1.02, CHCl₃).

EXAMPLE 2

Methyl fluorol[(1*R*,2*S*,3*R*,5*S*)-3-hydroxy-6-oxabicyclo[3.1.0]hex-2-yl]acetate 3



To a solution of olefin 2 (1.92 kg, 11.0 mol) in toluene (4.83 L) was added vanadyl acetylacetonate ($\text{VO}(\text{acac})_2$, 58.3 g, 0.22 mol) at 0 °C. After a solution of TBHP (5.7 M in decane, 38.6 mL) was added to the solution at 0 °C, the resulting suspension was allowed to warm to 14 °C.

- 5 Additional solution of TBHP (5.7 M in decane, 4.36 L) was slowly added to the reaction mixture over 50 min while maintaining the batch temperature between 14-28 °C. The resulting suspension was stirred for another 2 h, and then heated at 40 °C for 8 h. Excess TBHP was quenched with aqueous $\text{Na}_2\text{S}_2\text{O}_3$ solution (2.95 kg $\text{Na}_2\text{S}_2\text{O}_3$ and 4.71 kg H_2O), which was slowly added at 0 °C. The resulting mixture was stirred at 20 °C for 1.5 h. The disappearance of peroxides was confirmed by test paper. The
- 10 aqueous layer was separated and extracted with EtOAc (9.42 L x 2). The combined organic solutions were washed with brine (6.33 L). The brine layer was back-extracted with EtOAc (3.42 L x 4). GC assay of the combined organic solutions indicated product 3. The combined organic solutions were concentrated, and the resulting residue was purified by silica gel chromatography in a filter pot (first eluted with hexanes/EtOAc (4/1) then pure EtOAc). Analytically pure sample was prepared by flash
- 15 silica gel column chromatography (hexanes/MTBE) followed by recrystallization (EtOAc) as pale yellow crystals: mp 31-33 °C; ^1H NMR (400 MHz, CDCl_3) δ 5.01 (dd, $J = 48.3, 3.9$ Hz, 1 H), 4.13 (br s, 1 H), 3.86 (s, 3 H), 3.71 (m, 1 H), 3.59 (m, 1 H), 2.77 (dd, $J = 32.8, 3.9$ Hz, 1 H), 2.30 (br s, 1 H), 2.11 (m, 2 H); ^{13}C NMR (101 MHz, CDCl_3) δ 168.4 (d, $J = 24.1$ Hz), 88.1 (d, $J = 186.1$ Hz), 73.2 (d, $J = 1.6$ Hz), 58.4, 57.1 (d, $J = 5.6$ Hz), 52.8, 51.6 (d, $J = 19.3$ Hz), 37.7 (d, $J = 1.6$ Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -200.8 (dd, $J = 48.3, 32.8$ Hz); LRMS m/z 191 ($M + 1$), 189 ($M - 1$), 172 ($[M - \text{H}_2\text{O}]^+$), 59 ($[\text{COOCH}_3]^+$, base peak); $[\alpha]_D^{25} = -56$ (c 1.0, CHCl_3).
- 20

Analysis calculated for $\text{C}_8\text{H}_{11}\text{FO}_4$ C


50.53; H, 5.83; F, 9.99

Found: C, 50.36; H, 5.92; F, 10.05

25


EXAMPLE 2A

Methyl [(1R,2S,3R,5S)-3-hydroxy-6-oxabicyclo[3.1.0]hex-2-yl]acetate




To a solution of olefin 2' (50.0 mg, 0.320 mmol) in wet DMSO (6.4 μL H_2O in 1.2 mL DMSO) at rt was added NBS (68.4 mg, 0.384 mmol). After the resulting solution was stirred at rt for 4.5 h, another 10 mg of NBS was added. The reaction was further stirred at rt for 2 h, diluted with EtOAc, and washed with H_2O . The aqueous layer was extracted with EtOAc (twice), and the combined organic layer was dried over Na_2SO_4 . The solvent was removed under reduced pressure, and the resulting residue was taken in CH_2Cl_2 (1.2 mL). DBU (57.4 μL , 0.384 mmol) was added to the solution, which was stirred at rt for 18 h. The solvent was evaporated, and the resulting residue was purified by flash silica gel column chromatography to afford epoxide 3' as a mixture of diastereomers, which were inseparable by chromatography. The spectral data for the major isomer are as follows: ^1H NMR (CDCl_3 , 400 MHz) δ 3.80 (dd, $J = 11.6, 5.6$ Hz, 1 H), 3.72 (s, 3 H), 3.65 (m, 1 H), 3.61 (m, 1 H), 2.68 (dd, $J = 8.4, 7.2$ Hz, 1 H), 2.36 (d, $J = 11.6$ Hz, 1 H), 2.26 (dd, $J = 15.7, 7.2$ Hz, 1 H), 2.20 (dd, $J = 15.7, 8.4$ Hz, 1 H), 2.11 (d, $J = 15.3$ Hz, 1 H), 2.02 (dd, $J = 15.3, 5.6$ Hz, 1 H).

Under similar reaction conditions, the following epoxides were also prepared:



EXAMPLE 3

Methyl ((1R,2R,3R,5S)-3-([*tert*-butyl(dimethyl)silyl]oxy)-6-oxabicyclo[3.1.0]hex-2-yl)fluoroacetate 4



To a solution of epoxy alcohol 3 (1.60 kg, 8.40 mol) and DMF (3.40 L) was added imidazole (1.26 kg, 18.5 mol) at 10 °C. TBSCl (1.52 kg, 10.1 mol) was added to the reaction mixture while maintaining the batch temperature below 8 °C. The resulting solution was stirred at 5 °C for 10 min, then allowed to warm to 20 °C over 30 min and stirred for 2 h at the same temperature. The consumption of the starting alcohol was monitored by GC, and the reaction mixture was diluted with cold toluene (17.0 L, 5 °C). The resulting mixture was washed with H₂O (5.67 L), saturated aqueous NaHCO₃ (5.67 L), H₂O (5.67 L x 2), and brine (5.67 L). Assay of the organic solution indicated 4. Concentration of the solution gave 4 as yellow liquid, which was used for the next step without further purification.

Analytically pure sample was obtained by flash silica gel column chromatography (hexanes/MTBE) as colorless crystals: mp 28-30 °C; ¹H NMR (400 MHz, CDCl₃) δ 5.00 (dd, *J* = 48.2, 3.5 Hz, 1 H), 4.45 (m, 1 H), 3.85 (s, 3 H), 3.51 (m, 1 H), 3.42 (m, 1 H), 2.64–2.52 (dm, *J* = 34.5 Hz, 1 H), 2.14 (m, 1 H), 1.91 (m, 1 H), 0.88 (s, 9 H), 0.054 (s, 3 H), and 0.051 (s, 3 H); ¹³C NMR (101 MHz, CDCl₃) δ 168.8 (d, *J* = 24.1 Hz), 88.3 (d, *J* = 186.1 Hz), 75.4 (d, *J* = 1.6 Hz), 58.3, 57.2 (d, *J* = 7.2 Hz), 52.8 (d, *J* = 19.3 Hz), 52.7, 38.3, 25.9, 18.0, –4.5, and –4.7; ¹⁹F NMR (376 MHz, CDCl₃) δ –199.9 (dd, *J* = 48.2, 34.5 Hz); LRMS *m/z* 305 (*M* + 1), 121 (base peak); [α]_D²⁵ = –27 (*c* 1.0, CHCl₃).


Analysis calculated for C₁₄H₂₅FO₄Si

C, 55.23; H, 8.28; F, 6.24

Found: C, 55.27; H, 8.63; F, 6.31

EXAMPLE 4

Methyl (1*R*,2*R*,4*S*,5*S*,6*R*)-2-[[*tert*-butyl(dimethyl)silyl]oxy]-6-fluoro-4-hydroxybicyclo[3.1.0]hexane-6-carboxylate 5



To a solution of epoxide TBS-ether 4 (assay wt. 1.60 kg, 5.24 mol) in THF (16.1 L) was added a solution of Et₃Al (1.0 M in hexanes, 6.81 L, 6.81 mol), while maintaining the batch temperature at –60

°C over 1 h, and the resulting solution was stirred at -60 °C for 20 min. A solution of LHMDs (1.0 M solution in hexanes, 7.86 L, 7.86 mol) was added to the reaction mixture over 1 h while maintaining the batch temperature below -60 °C, and the reaction was aged at -60 °C. The progress of the reaction was monitored by GC. After complete consumption of the epoxide (6 h), an aqueous solution of citric acid (3 M, 10.5 L) was added over 1 h while maintaining the batch temperature below -50 °C. After MTBE (12.4 L) was added, the resulting suspension was gradually allowed to warm to 15 °C with stirring. The mixture turned to biphasic solution after addition of H₂O (4.93 L). The organic layer was separated and washed twice with saturated aqueous NaHCO₃ (11.1 L then 5.6 L). GC assay of the organic solution indicated compound 5. Concentration of the organic layer afforded crude alcohol as yellow oil which was used for the next reaction without further purification.

Analytically pure sample was obtained by flash silica gel column chromatography as colorless amorphous solid: ¹H NMR (400 MHz, CDCl₃) δ 4.47 (d, *J* = 4.4 Hz, 1 H), 4.34 (m, 1 H), 3.83 (s, 3 H), 2.44 (d, *J* = 6.8 Hz, 1 H), 2.37 (d, *J* = 11.2 Hz, 1 H), 2.25 (d, *J* = 6.8 Hz, 1 H), 2.07 (m, 1 H), 1.84 (m, 1 H), 0.91 (s, 9 H), 0.131 (s, 3 H), and 0.128 (s, 3 H); ¹³C NMR (101 MHz, CDCl₃) δ 169.2 (d, *J* = 26.5 Hz), 79.7 (d, *J* = 244.3 Hz), 74.1, 74.0, 52.9, 44.6 (d, *J* = 10.4 Hz), 37.9 (d, *J* = 12.0 Hz), 37.6 (d, *J* = 11.2 Hz), 25.8, 18.0, -4.8, -4.9; ¹⁹F NMR (376 MHz, CDCl₃) δ -217.1 (m); LRMS *m/z* 305 (*M* + 1), 304 (*M*), 303 (*M* - 1), 75 (base peak); [α]_D²⁵ = +7 (*c* 1.1, CHCl₃).


Analysis calculated for C₁₄H₂₅FO₄Si C

55.23; H, 8.28, F, 6.24

Found: C, 55.44; H, 8.46; F, 6.39

EXAMPLE 5

Methyl (1*R*,2*R*,5*S*,6*S*)-2-[[*tert*-butyl(dimethyl)silyl]oxy]-6-fluoro-4-oxobicyclo[3.1.0]hexane-6-carboxylate 6



To a solution of bicyclic mono-TBS-diol 5 (2.08 kg; 6.83 mol) in acetonitrile (8.0 L) at -5 °C was added acetic acid (0.70 L) and water (2.5 L), followed by RuCl₃ hydrate (14.20 g). To the mixture was added aqueous sodium hypochlorite solution (~13%; 7.0 L) over 2 h, keeping the temperature around 0 °C. The resulting mixture was stirred at 0 °C for another 1 h until all bicyclic mono-TBS-diol 5

disappeared, monitoring by TLC and NMR. The excess aqueous sodium hypochlorite was decomposed by the addition of isopropanol (0.70 L), aged at 0 °C for 15 min. The two layers were cut and the aqueous layer was discarded. The solution was used for the next reaction without further treatment.

Analytical pure sample was obtained by flash silica gel column chromatography (MTBE/hexane) as colorless crystals: mp 70 – 71 °C; ¹H NMR (400 MHz, CDCl₃): δ 4.66 (d, *J* = 5.4 Hz, 1 H), 3.86 (s, 3 H), 3.73 (s, 3 H), 2.73 (m, 2 H), 2.54 (dt, *J* = 19.1, 5.7 Hz, 1 H), 2.22 (dd, *J* = 19.1, 3.8 Hz, 1 H), 0.91 (s, 9 H), 0.13 (s, 3 H), 0.11 (s, 3 H); ¹³C NMR (101 MHz, CDCl₃): δ 206.2, 167.1 (d, *J* = 26.1 Hz), 78.9 (d, *J* = 246.4 Hz), 67.6 (d, *J* = 2.8 Hz), 53.4, 47.5 (d, *J* = 3.9 Hz), 42.0 (d, *J* = 11.4 Hz), 39.6 (d, *J* = 13.3 Hz), 25.7, 18.0, -4.76, and -4.78; ¹⁹F NMR (376 MHz, CDCl₃): δ -210.7; [α]_D²⁵ = + 58.2 (*c* 0.50, CH₃OH).

Analysis calculated for C₁₄H₂₃FO₄Si C

55.60; H, 7.67, F, 6.28

Found: C, 55.60; H, 7.56; F, 6.33

EXAMPLE 6

Methyl (1*R*,2*R*,5*S*,6*S*)-6-fluoro-2-hydroxy-4-oxobicyclo[3.1.0]hexane-6-carboxylate 7




The above organic layer, containing TBS-ketone 6 (6.83 mol) was warmed to 22 °C and 1 M HCl (1.37 L) was added. The mixture was stirred at 22-24 °C for 3.5 h until all TBS groups were removed. To the mixture was added saturated sodium bicarbonate solution (4.8 L). The mixture was stirred for 15 min, diluted with isopropyl acetate (20 L), and the organic layer was separated. The aqueous layer was back extracted with isopropyl acetate (6 L). The combined organic solutions were concentrated to dryness and the compound was purified by silica gel chromatography in a filter pot (first eluted with 30% MTBE in hexane, then MTBE alone) to give compound 7 as an off white crystal. Analytical pure sample was obtained by further flash silica gel column as colorless crystals: mp 61- 62 °C; ¹H NMR (400 MHz, CDCl₃): δ 4.92 (br s, 1 H), 3.85 (s, 3 H), 2.86 (dd, *J* = 6.2, 2.1 Hz, 1 H), 2.71 (d, *J* = 6.2 Hz, 1 H), 2.61 (dt, *J* = 19.4, 5.7 Hz, 1 H), 2.59 (br s, 1 H), 2.30 (dd, *J* = 19.4, 3.7 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃): δ 206.9, 167.0 (d, *J* = 26.2 Hz), 79.0 (d, *J* = 246.6 Hz), 67.0 (d, *J* = 3.1 Hz), 53.5, 46.8 (d, *J* = 4.2 Hz), 41.6 (d, *J* = 11.8 Hz), 39.4 (d, *J* = 13.1 Hz); ¹⁹F NMR (376 MHz, CDCl₃): δ -210.6; [α]_D²⁵ = + 77 (*c* 0.50, CH₃OH).

Analysis calculated for C₈H₉FO₄C
 51.07; H, 4.82, F, 10.10
 Found: C, 51.06; H, 4.83; F, 10.05

5

EXAMPLE 6A


Methyl (1*S*,2*R*,5*R*,6*R*)-2-hydroxy-4-oxobicyclo[3.1.0]hexane-6-carboxylate



TBS-ether **6'** (150 mg, 0.528 mmol) was treated with 1 M HCl (0.106 mL) in acetonitrile (0.8 mL) at rt for 2 h. The reaction was diluted with EtOAc, quenched by addition of a small amount of saturated aq. NaHCO₃, washed with H₂O and brine (twice), and dried over Na₂SO₄. The solvents were removed under reduced pressure, and the resulting residue was purified by flash silica gel column chromatography to afford hydroxy ketone **7'** as colorless solid: ¹H NMR (CDCl₃, 400 MHz) δ 4.60 (d, *J* = 5.2 Hz, 1 H), 3.72 (s, 3 H), 2.67 (dd, *J* = 5.2, 3.6 Hz, 1 H), 2.42 (dd, *J* = 5.2, 2.4 Hz, 1 H), 2.34 (dd, *J* = 18.9, 5.2 Hz, 1 H), 2.22 (br-s, 1 H), 2.08 (d, *J* = 18.9 Hz, 1 H), 1.93 (dd, *J* = 3.6, 2.4 Hz, 1 H); ¹³C NMR (CDCl₃, 101 MHz) δ 208.8, 169.8, 68.3, 52.5, 42.7, 36.2, 34.2, 25.2.

EXAMPLE 7

Methyl (1*S*,4*R*,4'*S*,5*R*,5'*S*,6*S*)-6-fluoro-4-hydroxy-4',5'-diphenylspiro[bicyclo[3.1.0]hexane-2,2'-[1.3]dioxolane]-6-carboxylate **8**




20

To a solution of hydroxy ketone **7** (1.09 kg; 5.76 mol) and CH₂Cl₂ (7.7 L) was added a solution of (*S,S*)-bis-*O*-TMS-hydrobenzoin (assay 2.01 kg; 5.60 mol) and CH₂Cl₂ (2.55 L). The solution was cooled to -20 °C. TfOH (50.9 mL; 0.576 mol) was charged through an addition funnel over 4 min at -15

~ -20 °C. The solution was warmed to -10 °C and aged at -10 °C for 1.5 h. An additional solution of (S,S)-bis-O-TMS-hydrobenzoin (assay 107 g; 0.298 mol) in CH₂Cl₂ (188g) was charged to the reaction mixture at -10 °C. The reaction was completed after 30 min additional age at -10 °C. The reaction was quenched by addition of pyridine (46.9 mL; 0.576 mol) at < -15 °C. The solution was warmed to -10 °C, washed with 5 wt% of cold aqueous solution of NaHCO₃ (3.75 L), 1 M cold aqueous HCl (8.6 L), 5 wt % cold aqueous NaHCO₃ (3.75 L), and 10 wt % cold aqueous NaCl (5.0 L) in turn, dried over Na₂SO₄ (1.5 kg). The solvent of the organic solution was switched into acetonitrile and used for the next reaction without further purification. HPLC assay of the solution at this point indicated the ketal alcohol 8. Analytically pure sample was obtained by flash silica gel column chromatography as colorless crystals: mp 118-120 °C; ¹H NMR (401 MHz, CDCl₃): δ 7.38-7.21 (m, 10 H), 4.89 (d, *J* = 8.3 Hz, 1 H), 4.83 (d, *J* = 8.3 Hz, 1 H), 4.51 (br s, 1 H), 3.89 (s, 3 H), 2.54-2.51 (m, 2 H), 2.43-2.37 (m, 2 H), 2.18 (br s, 1 H); ¹³C NMR (101 MHz, CDCl₃): δ 168.7 (d, *J* = 25.7 Hz), 136.6, 135.8, 128.7, 128.6, 128.5, 128.4, 126.9, 126.3, 117.7, 86.2, 86.1, 77.6 (d, *J* = 247.1 Hz), 71.1, 53.0, 45.7 (d, *J* = 7.8 Hz), 37.5 (d, *J* = 12.1 Hz), 36.7 (d, *J* = 11.9 Hz); ¹⁹F NMR (377 MHz, CDCl₃): δ -216.3.

EXAMPLE 8

Methyl (1*S*,4'*S*,5*R*,5'*S*,6*S*)-6-fluoro-4-oxo-4',5'-diphenylspiro[bicyclo[3.1.0]hexane-2,2'-[1.3]dioxolane]-6-carboxylate 9




To a solution of hydroxy ketal 8 (assay 2.04 kg, 5.31 mol) in acetonitrile (36.7 L) was added RuCl₃ hydrate (8.25 g) followed by water (2.0 L) and acetic acid (0.41 L) at 0 °C. Aqueous sodium hypochloride solution (~13%, 5.37 L) was added to the reaction solution slowly over 19 min, while maintaining the reaction temperature below 4 °C. The solution was aged at 0-3.5 °C for 2 h. The reaction was quenched by addition of isopropanol (2.2 L) at 3.5 °C. After 30 min aging at the same temperature, aqueous cold NaHCO₃ (5 wt%, 10.7 L) was added to the mixture over 12 min between 0.4 and 3.3 °C. The resulting slurry was stirred for 30 min at 3 °C, and the product 9 was filtered. The wet cake was washed with cold water (2 L x 2) and dried to give the first crop of the ketal ketone 9. The filtrate and washes were combined and the layers were separated. The organic layer was concentrated in

vacuo. The resulting slurry was filtered. The cake was washed with water (0.48 L x 2) and was recrystallized from acetonitrile (1.8 L) and water (1.08 L) to give the second crop of ketal ketone **9**. Analytically pure sample was obtained by flask silica gel column chromatography as colorless crystals: mp 58.5-59.5 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.40-7.34 (m, 6 H), 7.28-7.25 (m, 4 H), 4.97 (d, *J* = 8.4 Hz, 1 H), 4.88 (d, *J* = 8.4 Hz, 1 H), 3.93 (s, 3 H), 3.10 (dd, *J* = 6.4, 2.0 Hz, 1 H), 2.94 (d, *J* = 4.0 Hz, 2 H), 2.87 (d, *J* = 6.4 Hz, 1 H); ¹³C NMR (101 MHz, CDCl₃): δ 201.5, 166.9 (d, *J* = 25.7 Hz), 136.1, 135.3, 129.0, 128.8, 128.72, 128.69, 126.8, 126.5, 110.8, 86.3, 85.8, 78.9 (d, *J* = 251.6 Hz), 53.6, 48.3 (d, *J* = 3.3 Hz), 42.2 (d, *J* = 13.2 Hz), 41.7 (d, *J* = 12.0 Hz); ¹⁹F NMR (376 MHz, CDCl₃): δ -208.5.

EXAMPLE 9


(1*S*,4'*S*,5*R*,5'*S*,6*S*)-4-Amino-4-cyano-6-fluoro-4',5'-diphenylspiro[bicyclo[3.1.0]hexane-2,2'-[1.3]dioxolane]-6-carboxamide **10**



To a solution of 7 M ammonia in methanol (7.4 L, 47.8 mol) and Ti(OiPr)₄ (1.77 L, 5.93 mol) at 23° C was added ketal ketone **9** (2.11 kg, 1.89 kg as pure **9**, 4.94 mol). The mixture was stirred for 4 h at 20-23 °C. The mixture was cooled to -12 °C, and TMSCN (505 g, 5.09 mol) was added. The mixture was warmed to -4.5 °C and stirred at that temperature for 16 h. The mixture was filtered and crystals were washed with cold MeOH (7.0 L), and dried at 20-25 °C at reduced pressure to afford aminonitrile **10** as a colorless solid. Analytically pure sample was prepared by silica gel column chromatography as colorless crystals: mp. 196.9-197.4 °C. ¹H NMR (400 MHz, DMSO-d₆): δ 8.04 (s, 1 H), 7.78 (s, 1 H), 7.38-7.25 (m, 10 H), 5.15 (d, *J* = 8.8 Hz, 1 H), 4.81 (d, *J* = 8.8 Hz, 1 H), 2.86, (s, 2 H), 2.78 (dd, *J* = 14.5, 3.2 Hz, 1 H), 2.63 (d, *J* = 6.8 Hz, 1 H), 2.46 (d, *J* = 6.8 Hz, 1 H), and 2.23 (dd, *J* = 14.5, 4.4 Hz, 1 H). ¹³C NMR (101 MHz, DMSO-d₆): δ 168.7 (d, *J* = 23.3 Hz), 136.5, 135.9, 128.6, 128.5, 128.5, 127.1, 126.9, 123.4, 115.1, 84.7, 84.3, 81.1 (d, *J* = 255.4 Hz), 54.6, 48.3 (d, *J* = 7.2 Hz), 36.6 (d, *J* = 11.2 Hz), and 35.9 (d, *J* = 10.4 Hz). ¹⁹F NMR (377 MHz, DMSO-d₆): δ -211.6.

EXAMPLE 10


(1*R*,2*S*,5*S*,6*S*)-2-Amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid **11**



A mixture of aminonitrile **10** (1.63 kg crude, 1.55 kg pure basis), HOAc (3.25 L), H₂O (3.25 L), and conc. HCl (6.50 L) was heated to 75±2 °C for 4 h. ¹⁹F NMR showed that the reaction was complete. The solution was cooled to 18 °C and extracted with CH₂Cl₂ (1 x 9 L and 2 x 5 L). The aqueous layer
 5 was concentrated at 10-25 torr and 50 °C internal temperature to ~ 2 L. The resulting slurry was cooled to 0 °C and stirred for 1 h. The cooled slurry was filtered, and the cake containing HCl salt of product **11** was maintained under vacuum filtration for 5-10 min to remove as much of the filtrate as possible. The cake of HCl salt from above was added to water (5.0 L) at 65 °C, and rinsed in with hot H₂O (300 mL). The solution was allowed to cool to 17 °C over 45 min. The pH was adjusted to 1.25 with 50% NaOH
 10 (230 mL). The slurry was cooled to 0 °C and stirred for 45 min. The slurry was filtered, washed with H₂O (2 x 1 L), and dried under nitrogen to afford the off-white crystalline product **11** as monohydrate. Analytically pure HCl salt of **11** was obtained from 20% HCl: mp. 195-220 (decomp); ¹H NMR (401 MHz, DMSO-d₆): δ 8.99 (s, 2 H), 3.08 (dd, *J* = 6.4, 1.6 Hz, 1 H), 3.02 (d, *J* = 6.4 Hz, 1 H), 2.86 (dd, *J* = 18.5, 3.6 Hz, 1 H), 2.57 (dd, *J* = 18.5, 4.8 Hz, 1 H); ¹³C NMR (101 MHz, DMSO-d₆): δ 201.3 (d, *J* =
 15 2.7 Hz), 170.4, 166.3 (d, *J* = 25.7 Hz), 78.9 (d, *J* = 247.0 Hz), 58.1 (d, *J* = 1.5 Hz), 40.6 (d, *J* = 13.1 Hz), 36.8 (d, *J* = 11.1 Hz); ¹⁹F NMR (377 MHz, DMSO-d₆): δ -204.8; Cl Titration 13.96 % (Theory 13.98 %).

EXAMPLE 11

20 Methyl ((1*R*,2*R*,3*R*,5*S*)-3-[[*tert*-butyl(dimethyl)silyl]oxy]-6-oxabicyclo[3.1.0]hex-2-yl)acetate



25 To a solution of olefin **12** (4.25 g, 27.2 mmol) in toluene (10.8 mL), was added vanadyl acetylacetonate (VO(acac)₂, 289 mg, 1.09 mmol, 4 mol %). A solution of TBHP (14.3 mL, 81.6 mmol, 5.7 M in decane)

was added over 30 min while maintaining the internal temperature below 28 °C. The resulting mixture was stirred at rt for 5.5 h and quenched by addition of saturated aq. Na₂S₂O₃. The aqueous layer was separated and extracted by ethyl acetate (x 5). The combined organic layers were washed with brine and dried over Na₂SO₄. Solvents were evaporated, and the resulting residue was purified by flash silica gel chromatography to afford epoxy alcohol **13** as colorless liquid, which contained inseparable byproducts. This alcohol (3.21 g) was treated with imidazole (2.78 g, 40.9 mmol) and TBSCl (3.36 g, 22.3 mmol) in DMF (7.2 mL) at ambient temperature to convert the hydroxyl group to the TBS-ether. The reaction mixture was stirred at rt for 2.5 h and then treated with MTBE (36 mL) and H₂O (12 mL). The organic layer was separated, washed with saturated aq. NaHCO₃, H₂O and brine, and dried over Na₂SO₄.

Solvent was evaporated, and the resulting residue was purified by flash silica gel chromatography to afford TBS-ether **14** as a colorless liquid: ¹H NMR (CDCl₃, 400 MHz) δ 4.08 (m, 1 H), 3.72 (s, 3 H), 3.49 (m, 1 H), 3.37 (m, 1 H), 2.49 (m, 1 H), 2.31 (d, *J* = 7.2 Hz, 1 H), 2.31 (m, 1 H), 2.09 (m, 1 H), 1.93 (m, 1 H), 0.88 (s, 9 H) 0.04 (s, 3 H), 0.03 (s, 3 H); ¹³C NMR (CDCl₃, 101 MHz) δ 171.9, 77.0, 60.4, 57.4, 51.7, 46.4, 37.2, 34.6, 25.8, 18.0, -4.7; LRMS *m/z* 287 (*M* + 1), 286 (*M*), 285 (*M* - 1), 169 (base peak);


Analysis calculated for C₁₄H₂₆O₄Si C

58.70; H, 9.15

Found C, 58.45; H, 9.49

EXAMPLE 12

Methyl (1*S*,2*R*,4*S*,5*R*,6*S*)-2-{[*tert*-butyl(dimethyl)silyl]oxy}-4-hydroxybicyclo[3.1.0]hexane-6-carboxylate



To a solution of epoxide **14** (3.52 g, 12.3 mmol) in THF (37.8 mL) at -70 °C, was added a solution of Et₃Al (16.0 mL, 16.0 mmol, 1 M in hexanes). After the resulting solution was stirred at -70 °C for 10 min, a solution of LHMDS (18.4 mL, 18.4 mmol, 1 M in hexanes) was added slowly over 30 min. The resulting solution was stirred at -70 °C for 100 min and quenched by addition of aq. citric acid (24.9 mL, 3 M). After toluene (24.9 mL) was added, the resulting mixture was allowed to warm to ambient temperature, and H₂O (11.7 mL) was added. The aqueous layer was separated and extracted with MTBE

(20 mL). The combined organic layers were washed with saturated aq. NaHCO_3 (36 mL x 2) and brine and dried over Na_2SO_4 . Solvent was evaporated, and the resulting residue was purified by flash silica gel column chromatography to afford bicyclic alcohol **15** as colorless oil: ^1H NMR (CDCl_3 , 400 MHz) δ 4.34 (d, $J = 4.4$ Hz, 1 H), 4.18 (dd, $J = 11.6, 4.4$ Hz, 1 H), 3.68 (s, 3 H), 2.46 (d, $J = 11.6$ Hz, 1 H), 2.26 (dd, $J = 6.0, 2.8$ Hz, 1 H), 2.10 (dd, $J = 6.0, 2.8$ Hz, 1 H), 1.67 (d, $J = 15.3$ Hz, 1 H), 1.49 (dt, $J = 15.3, 4.4$ Hz, 1 H), 1.16 (t, $J = 2.8$ Hz, 1 H), 0.90 (s, 9 H), 0.13 (s, 3 H), 0.11 (s, 3 H); ^{13}C NMR (CDCl_3 , 101 MHz) δ 172.2, 73.8, 73.6, 51.9, 40.3, 33.3, 33.0, 25.7, 21.8, 17.9, -4.8, -5.0; LRMS m/z 287 ($M + 1$), 286 (M), 285 ($M - 1$), 169 (base peak);


Analysis calculated for $\text{C}_{14}\text{H}_{26}\text{O}_4\text{Si}$ C

58.70; H, 9.15.

Found C, 58.55; H, 9.34

EXAMPLE 13


Methyl (1*S*,2*R*,4*S*,5*R*,6*R*)-2-[[*tert*-butyl(dimethyl)silyl]oxy]-4-[[4-(4-methylphenyl)sulfonyl]oxy]bicyclo[3.1.0]hexane-6-carboxylate



To a stirred solution of alcohol **15** (929 mg, 3.24 mmol) in CH_2Cl_2 (3.8 mL) at 0 °C, were added pyridine (2.62 mL, 32.4 mmol) and *p*-toluenesulfonyl chloride (1.24 g, 6.49 mmol). The resulting mixture was allowed to warm to ambient temperature and stirred at the same temperature for 15 h. Saturated aq. NaHCO_3 (5 mL) was added to the reaction mixture, and the resulting mixture was stirred at room temperature for 1 h. The aqueous layer was separated and extracted with MTBE (10 mL x 2). The combined organic layer was washed with 1 M HCl (40 mL), saturated aq. NaHCO_3 (10 mL) and brine (10 mL) and dried over Na_2SO_4 . Solvent was evaporated, and the resulting residue was purified by flash silica gel chromatography to afford *p*-toluenesulfonate ester **16** as colorless solid: ^1H NMR (CDCl_3 , 400 MHz) δ 7.81 (d, $J = 8.0$ Hz, 2 H), 7.33 (d, $J = 8.0$ Hz, 2 H), 5.02 (d, $J = 5.2$ Hz, 1 H), 4.27 (d, $J = 4.8$ Hz, 1 H), 3.65 (s, 3 H), 2.45 (s, 3 H), 2.30 (dd, $J = 5.6, 2.8$ Hz, 1 H), 2.15 (dd, $J = 5.6, 3.2$ Hz, 1 H), 1.85 (d, $J = 16.5$ Hz, 1 H), 1.64 (ddd, $J = 16.5, 5.2, 4.8$ Hz, 1 H), 1.06 (dd, $J = 3.2, 2.8$ Hz, 1 H), 0.86 (s, 9 H), 0.07 (s, 3 H), 0.04 (s, 3 H); ^{13}C NMR (CDCl_3 , 101 MHz) δ 171.4, 144.5, 134.5, 129.7, 127.6, 82.4, 72.7, 52.0, 40.0, 34.8, 31.3, 25.7, 21.6, 21.1, 17.9, -4.7, -4

EXAMPLE 14

Methyl (1*S*,2*R*,4*S*,5*R*,6*R*)-2-hydroxy-4-[[[(4-methylphenyl)sulfonyl]oxy]bicyclo[3.1.0]hexane-6-carboxylate




TBS-ether **16** (1.86 g, 4.22 mmol) was treated with 0.84 mL of aq HCl (1 M) in acetonitrile (9.4 mL) at rt for 4 h. The reaction was quenched by addition of saturated aq. NaHCO₃ (8.7 mL) and MTBE (20 mL).

The aqueous layer was separated and extracted with MTBE (10 mL x 2). The combined organic layer was dried over Na₂SO₄ and concentrated under reduced pressure. Treatment of the resulting residue with hexanes gave crystals, which were filtered and recrystallized from hexanes/EtOAc to afford pure alcohol **17** as colorless crystals: ¹H NMR (CDCl₃, 400 MHz) δ 7.82 (d, *J* = 8.0 Hz, 2 H), 7.38 (d, *J* = 8.0 Hz, 2 H), 5.01 (d, *J* = 5.2 Hz, 1 H), 4.24 (d, *J* = 5.2 Hz, 1 H), 3.67 (s, 3 H), 2.47 (s, 3 H), 2.33-2.28 (m, 2H), 1.93 (d, *J* = 16.5 Hz, 1 H), 1.67 (dt, *J* = 16.5, 5.2 Hz, 1 H), 1.16 (t, *J* = 3.0 Hz, 1 H); ¹³C NMR (CDCl₃, 101 MHz) δ 171.1, 145.1, 133.9, 130.1, 127.8, 83.2, 72.7, 52.2, 39.3, 33.9, 30.8, 21.8, 21.7.

EXAMPLE 15

Methyl (1*R*,5*S*,6*S*)-4-oxobicyclo[3.1.0]hex-2-ene-6-carboxylate




To a solution of DMSO (0.404 mL, 5.70 mmol) in CH₂Cl₂ (2.6 mL), was added a solution of trifluoroacetic anhydride (0.604 mL, 4.28 mmol) in CH₂Cl₂ (1.5 mL) at -78 °C. The resulting solution was stirred at -78 °C for 30 min, and a solution of alcohol **17** (0.885 g, 2.85 mmol) in CH₂Cl₂ (4.1 mL) was added (flask was rinsed with 1.0 mL CH₂Cl₂). After the resulting solution was stirred at -78 °C for 30 min, Et₃N (1.59 mL, 11.4 mmol) was slowly added. The resulting mixture was stirred at -78 °C for

2.5 h, and the reaction was quenched by addition of H₂O (5 mL). After MTBE (10 mL) was added, the resulting mixture was allowed to warm to rt, and the aqueous layer was separated and extracted with MTBE (10 mL). The combined organic layer was washed with 1 M HCl (15 mL), saturated aq NaHCO₃ (10 mL), H₂O (10 mL) and brine (10 mL) and dried over Na₂SO₄. The solvent was evaporated, and the resulting residue was purified by flash silica gel column chromatography to afford α,β -unsaturated ketone **18** as pale yellow crystals: ¹H NMR (CDCl₃, 400 MHz) δ 7.61 (ddd, *J* = 5.6, 2.4, 0.8 Hz, 1 H), 5.74 (d, *J* = 5.6 Hz, 1 H), 3.71 (s, 3 H), 2.96 (m, 1 H), 2.62 (m, 1 H), 2.27 (m, 1 H); ¹³C NMR (CDCl₃, 101 MHz) δ 203.1, 168.4, 159.5, 129.7, 52.3, 45.4, 30.0, 28.9.


EXAMPLE 16

Methyl (1*S*,2*R*,5*R*,6*R*)-2-[[*tert*-butyl(dimethyl)silyl]oxy]-4-oxobicyclo[3.1.0]hexane-6-carboxylate (21)



To a solution of DMSO (0.358 mL, 5.04 mmol) in CH₂Cl₂ (2.5 mL) was added dropwise a solution of trifluoroacetic anhydride (0.534 mL, 3.78 mmol) in CH₂Cl₂ (1.3 mL), while maintaining the reaction temperature below -70 °C. The resulting solution was stirred at -78 °C for 55 min. A solution of alcohol **15** (722 mg, 2.52 mmol) in CH₂Cl₂ (3.7 mL + 1.0 mL rinse) was added dropwise, while maintaining the inside temperature below -75 °C. After stirring at -78 °C for 30 min, triethylamine (1.05 mL, 7.56 mmol) was added slowly over 15 min, maintaining the reaction temperature below -74.5 °C. The resulting mixture was stirred at -78 °C for 30 min and allowed to warm to -20 °C over 20 min. The reaction was further stirred at -20 °C for 30 min and quenched by addition of H₂O. The organic layer was separated, diluted with MTBE, washed with 0.5 M HCl, H₂O, saturated aq. NaHCO₃, and brine, and dried over Na₂SO₄. Solvent was removed under reduced pressure, and the resulting residue was purified by flash silica gel column chromatography to afford colorless solid **21** (673 mg, 94% yield): ¹H NMR (CDCl₃, 400 MHz) δ 4.52 (d, *J* = 5.2 Hz, 1 H), 3.72 (s, 3 H), 2.57 (dd, *J* = 5.2, 3.6 Hz, 1 H), 2.40 (m, 1 H), 2.28 (dd, *J* = 18.5, 5.2 Hz, 1 H), 1.99 (d, *J* = 18.5 Hz, 1 H), 1.87 (dd, *J* = 3.6, 2.8 Hz, 1 H), 0.89 (s, 9 H), 0.11 (s, 3 H), 0.09 (s, 3 H); ¹³C NMR (CDCl₃, 101 MHz) δ 209.2, 170.0, 68.8, 52.4, 43.2, 36.8, 34.5, 25.7, 25.0, 18.0, -4.7, -4.8.

EXAMPLE 17

Methyl (1*S*,5*R*,6*R*)-4-oxobicyclo[3.1.0]hex-2-ene-6-carboxylate (22)

TBS ether **21** (50.0 mg, 0.176 mmol) was treated with DBU (0.0789 mL, 0.528 mmol) in CH₂Cl₂ (0.9 mL) at rt for 1 h. The reaction was diluted with MTBE, washed with 1 M HCl and brine (twice), and dried over Na₂SO₄. Solvent was removed under reduced pressure, and the resulting residue was purified by flash silica gel column chromatography to afford colorless solid **22**: $[\alpha]_D^{20} +272.2$ (*c* 1.1, CHCl₃). The other spectra were identical to those of the α,β -unsaturated ketone **18** obtained in Example 15.

Characterization of Polymorph of the hydrochloride salt of (1*R*,2*S*,5*S*,6*S*)-2-Amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid **11**.

X-ray powder diffraction studies are widely used to elucidate molecular structures, crystallinity and polymorphism. X-ray powder diffraction (XRPD) patterns were collected for the crystal form of a sample of the HCl salt obtained in Example 10, using a Phillips diffractometer. Measurements were made from 3.0080 degrees to 39.9830 degrees (2 theta).

XRPD is depicted at Figure 1. The following reflections can be used to identify the crystal form:

Scan Parameters

Measurement Date / Time:	7/18/2003 10:6
Raw Data Origin:	PHILIPS-binary (scan) (.RD)
Scan Axis:	Gonio
Start Position [$^{\circ}2\theta$.]:	3.0080
End Position [$^{\circ}2\theta$.]:	39.9830
Step Size [$^{\circ}2\theta$.]:	0.0170
Scan Step Time [s]:	10.1500
Scan Type:	CONTINUOUS
Offset [$^{\circ}2\theta$.]:	0.0000

Anode Material: Cu
 Generator Settings: 40 kV, 50 mA
 Spinning: Yes

5 The peak list for the XRPD is depicted below, in Table 1:

Table 1- Peak List

<u>Pos.[°2Th.]</u>	<u>Heights[cts]</u>	<u>FWHM[°2Th.]</u>	<u>d-spacing[Å]</u>	<u>Rel. Int.[%]</u>
16.5056	260.27	0.1171	5.37086	28.52
19.6239	261.89	0.1673	4.52388	28.70
21.9330	189.45	0.1338	4.05255	20.76
23.1656	535.89	0.1171	3.83964	58.72
26.4349	912.56	0.1171	3.37172	100.00
30.2118	242.15	0.2007	2.95827	26.54
32.8470	633.43	0.2007	2.72671	69.41
33.5963	108.10	0.2007	2.66759	11.85
34.6396	70.31	0.4015	2.58960	7.70
37.2009	87.95	0.2676	2.41698	9.64

10 Thus, in one embodiment, the polymorphic form of (1*R*,2*S*,5*S*,6*S*)-2-Amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid HCl has a d-spacing determined by x-ray powder diffraction, CuK alpha, of about 5.37 angstroms. In other embodiments, the polymorphic form of (1*R*,2*S*,5*S*,6*S*)-2-Amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid HCl has at least one d-spacing determined by x-ray powder diffraction, CuK alpha, of about 4.52, 4.05, 3.84, 3.37, 2.96, 2.73,
 15 2.67, 2.59 or 2.42 angstroms.

Differential Scanning Calorimetry (DSC) of the sample of the HCl salt obtained in Example 10 was carried out using a TA Instruments DSC 2910 instrument at a heating rate of 10°C/min from 20°C to 175 °C and at 2°C/min from 175°C to 255 °C under a nitrogen atmosphere in an open pan. The results are depicted in Figure 2. The results showed a broad melting point with an onset temperature of about
 20 184 °C followed by exothermic decomposition above 227 °C.

Thus, in one embodiment, the polymorphic form of (1*R*,2*S*,5*S*,6*S*)-2-Amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid HCl has a Differential Scanning Calorimetry extrapolated onset melting temperature of about 184°C.

The following abbreviations are used throughout the text:

Me: methyl

Et: ethyl

iPr: isopropyl

5 Bu: butyl

Ac: acetyl

DBU: 1,8-diazabicyclo [5.4.0] undec-7-ene

NBS: N-bromo succinimide

NIS: N-iodo succinimide

10 DMF: N, N'-dimethylformamide

THF tetrahydrofuran

TBHP: tertiary butyl hydroperoxide

MTBE: methyl tertiary butyl ether

LDA: lithium diisopropylamide

15 TBS: tertiary butyldimethylsilyl

TMS: trimethylsilyl

TES: triethylsilyl

DMSO: dimethylsulfoxide

TfOH: trifluoromethanesulfonic acid

20 LHMDs lithium hexamethyldisilazide

Ts: *para*-toluenesulfonyl (tosyl)

HPLC: high performance liquid chromatography

GC: gas chromatography

NMR: nuclear magnetic resonance

25 DSC: differential scanning calorimetry

TLC: thin layer chromatography

XRPD: x-ray powder diffraction

rt: room temperature

30 While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. For example, reaction conditions other than the particular conditions as set forth herein above may be applicable as a consequence of variations in the

reagents or methodology to prepare the compounds from the processes of the invention indicated above. Likewise, the specific reactivity of starting materials may vary according to and depending upon the particular substituents present or the conditions of manufacture, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be defined by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

It is further to be understood that all values are approximate, and are provided for description. Patents, patent applications, publications, product descriptions, and protocols are cited throughout this application, the disclosures of which are incorporated herein by reference in their entireties for all purposes.